Objective: 25 Joint pain is the major clinical symptom of arthritis that affects millions of people. 26
Introduction 71
Peripheral sensitization, manifested by an increase in the excitability of dorsal root ganglion 72 (DRG) neurons, underlies many chronic pain pathologies, such as inflammatory arthritis (1) . 73 DRG neurons display great heterogeneity, based upon both gene expression (2,3) and 74 functional attributes (4), and this heterogeneity is further compounded by target innervation 75 (5, 6) . The variation in DRG neurons offers a unique opportunity to selectively tune the 76 excitability of a distinct subset of DRG neurons in order to provide pain relief with reduced 77 side-effects. For example, we have recently shown that the excitability of knee-innervating 78 DRG neurons (identified by retrograde tracing) is increased in a mouse model of inflammatory 79 joint pain (7) and after incubation with human osteoarthritis (OA) synovial fluid samples (8) . 80
These results suggest that modulation of the knee-innervating DRG neuron subset (knee 81 neurons) could help control arthritic pain. 82 83 One way of modulating neuronal excitability is to induce expression of inhibitory or excitatory 84 designer receptors exclusively activated by exogenous chemical actuators which by themselves 85 do not have any endogenous effects. Modified muscarinic receptor based designer receptors 86 activated by designer drugs (DREADDs) is a technology based on this principle that can 87 increase or decrease neuronal (mostly in the central nervous system, CNS) firing, which 88 consequently affects a variety of behaviors (reviewed in (9,10)), such as enhanced feeding (11) 89 or decreased wakefulness (12). In the peripheral nervous system (PNS), activation of the 90 inhibitory DREADD hM4D(Gi) in voltage-gated sodium channel 1.8 (NaV1.8) expressing DRG 91 neurons decreased knee hyperalgesia and mechanical allodynia, along with a decrease in DRG 92 neuron firing, in mice with early experimental OA pain induced by surgical destabilization of 93 the medial meniscus (13). This attenuation of hyperalgesia was at a similar level when compared 94 to administration of 10 mg/kg morphine, thus suggesting that peripherally acting analgesics can 95 be comparably potent to well-established opioids. Similarly, activating Gi-DREADD in 96 transient receptor potential vanilloid 1 (TRPV1) expressing DRG neurons (14) increased the 97 heat pain threshold and reduced neuronal excitability in mice. Both of these studies used 98 transgenic mice and therefore are less translatable across species due to the technical difficulties 99 associated with targeting sensory neuron sub-populations in species without such transgenic 100 tractability. In wild-type mice, Gi-DREADD delivered intraneurally to the sciatic nerve via 101 adeno-associated virus 6 (AAV6) was able to increase both mechanical and thermal thresholds 102 (15). Importantly however, none of these studies were specific to DRG neuron subsets 103 innervating specific organs. 104
105
AAVs are useful tools for gene transfer that have been used for gene therapy in a variety of 106 human diseases (16), with multiple AAV-based clinical trials currently underway for arthritis 107 (Clinical trial # NCT02727764, NCT02790723 (17)). AAVs can be utilized in conjunction with 108 DREADD technology to selectively modulate neuronal activity of specific neuronal circuitry. 109
Indeed, this has been achieved in the CNS (18). However, delivering genes by AAV injection 110 into a peripheral organ to DRG neurons is challenging because of the low transduction 111 capability of AAVs and the large anatomical distances involved in the PNS (19). A variety of 112 AAV serotypes have shown little efficacy in transducing DRG neurons when injected sub-113 cutaneously, intra-muscularly or intra-plantarly in adult mice (20,21). To date direct injection 114 into DRG (22) or intrathecal injection (23,24) are the best ways for transducing DRG neurons, 115 however, these routes of administration are invasive, technically complicated to perform and 116 do not enable transduction of neurons innervating a defined target. In the present study, we 117 provide evidence that the PNS specific AAV serotype, AAV-PHP.S (19), can infect DRG 118 neurons with functional cargo following injection into the knee joint. Furthermore, using the 119 inhibitory DREADD, hM4D(Gi), as a cargo, we show that its activation normalizes the 120 inflammatory pain induced deficit in digging behavior in mice, which is an ethologically 121 relevant spontaneous pain measure indicating well-being (25). This study thus extends the use 122 of AAV and DREADD technologies to study DRG neurons infected from a peripheral organ, 123 which can have future clinically-relevant applications in controlling pain pathologies. AAV-PHP.S-CAG-tdTomato (Addgene #59462-PHP.S) was purchased from Addgene. AAV 157 plasmids for DREADD viruses were purchased from Addgene (Table S1 ) and packaged at the 158 European Molecular Biology Laboratory, Rome as has been described previously (26). Briefly, 159 ten 150 mm dishes of HEK293T (ATCC) cells were triple transfected with plasmids (Table S1 ) 160 of AAV-PHP.S, helper (Agilent) and cargo in a 1:4:1 ratio with PEI reagent (1:3 plasmid to PEI 161 ratio, Sigma). Three days after transfection, cells and media were collected and this mixture 162 was centrifuged at 3700xg at 4°C to remove debris and then concentrated by ultrafiltration using 163 All behavioral experiments were carried out between 10:00 and 13:00 in the presence of one 187 male and one female experimenter. Mice were assigned randomly to control and experimental 188 groups and at least two cohorts of mice (8-12 mice in each group) were assessed in each group 189 on separate days. Mice were trained on digging and rotarod one day before the test days. The 190 following groups were tested in this study: 191 1. Compound 21 (C21) controls: Behavioral tests (described below) were performed on 192 mice with no knee injections 20 min before and after C21 (2 mg/kg diluted in sterile 193 saline from a stock of 100 mM in ethanol, i.p., Tocris) injection. Digging behavior was measured as an assessment of spontaneous pain as described before (7) 204 for three min in a standard cage with a wire lid, filled with Aspen midi 8/20 wood chip bedding 205 (LBS Biotechnology). For training, mice were habituated in the test room in their home cages 206 for 30 min then they were allowed to dig twice for 3 min with 30 min break in between. On 207 each subsequent test day, mice were habituated and tested once on the 3 min paradigm. Test 208 sessions were video recorded from which the digging duration was later independently coded 209 by the experimenters, blinded to the conditions. Number of dig sites (burrows) was coded on 210 test days by the experimenters. 211 212 Rotarod 213
Locomotor function and coordination of mice were tested using a rotarod apparatus (Ugo Basile 214 7650). Mice were tested on a constant speed rotarod at 7 rpm for 1 min, then in an accelerating 215 program (7-40 rpm in 5 min) for 6 min. The same protocol was used to train mice one day 216 before testing. Mice were removed from the rotarod after two passive rotations or when they 217 fell from the rotarod. Mice were video recorded on test days and one experimenter blinded to 218 the conditions coded these videos for latency(s) to passive rotation or fall. 219 220
Dynamic weight bearing 221
Deficit in weight bearing capacity is a characteristic measure of spontaneous inflammatory pain 222 behavior and we measured this behavior using a dynamic weight bearing (DWB) device 223 (Bioseb) in freely moving mice for 3 min. Animals were not trained in this device and coding 224 was done by one experimenter, blinded to the conditions. In at least 1 min 30 sec of the 3 min 225 recording, fore-and hind paw prints were identified using the two highest confidence levels 226 (based on correlation between manual software algorithm tracking) of the in-built software, at 227 least 30 s of which was manually verified. 228
DRG neuron culture 230
Lumbar DRG (L2-L5) were collected from a subset of mice in the vehicle group 3-4 weeks 231 after virus injections in ice cold dissociation media (as before (7)). DRG were then 232 enzymatically digested followed by mechanical trituration (7). Dissociated DRG neurons, thus 233 isolated, were then plated onto poly-D-lysine and laminin coated glass bottomed dishes 234 (MatTek, P35GC-1.5-14-C) in DRG culture medium contained L-15 Medium (1X) + 235
GlutaMAX-l, 10% (v/v) fetal bovine serum, 24 mM NaHCO3, 38 mM glucose, 2% 236 penicillin/streptomycin and maintained overnight (8-10-hours) in a humidified, 37 °C, 5% CO2 237 incubator before recording. IgorPro software (Wavemetrics) as described before (7). Neurons were excluded from analysis 255 if they did not fire an AP in response to current injections. Zamboni's fixative for 1-hour, followed by overnight incubation in 30% (w/v) sucrose (in PBS) 263 at 4 °C for cryo-protection. DRG were then embedded, snap-frozen, sectioned and stained as 264 described previously (7) using anti-TRPV1 antibody (1:500, Alomone, AGP-118, anti-guinea 265 pig polyclonal) with Alexa-488 conjugated secondary antibody (1:500, Jackson Laboratory, 266 706-545-148, anti-guinea pig). Positive neurons were scored as has been reported previously 267 thus we hypothesized that this AAV serotype would be able to transduce DRG neurons when 289 injected intra-articularly into the knee joint. Consistent with our hypothesis, when AAV-PHP.S-290 CAG-dTomato and the commonly used retrograde tracer fast blue (FB) were co-injected 291 unilaterally into one knee of mice (n = 3, female), we observed both FB and virus labelling (Fig 292 1A ). In agreement with previous reports using FB and other retrograde tracers (7,27,28), we 293 observed a similar proportion of labelling in the lumbar DRG with FB and AAV-PHP.S-CAG-294 dTomato ( Fig 1B) . Across L2-L5 DRG, there was ~ 40 % co-labelling of neurons with FB and 295 AAV-PHP.S-CAG-dTomato suggesting that neither retrograde tracer is able to label the entire 296 knee neuron population ( Fig 1C, Fig S1) . However, area analysis of the labelled neurons 297 suggests that similar sized neurons are targeted by both strategies (Fig S1) . Furthermore, we 298 observed minimum labelling in the contralateral side ( Fig S1) . Previous reports suggest that ~40 299 % of knee neurons are TRPV1 expressing putative nociceptors (7,28). Similarly, with 300 immunohistochemistry analysis of DRG neurons, we find that ~30 % of viral labelled and FB 301 labelled neurons (mostly small diameter neurons) express TRPV1 ( Fig 1D, Fig S1) suggesting 302 that viral transduction did not substantially alter expression of the nociceptive protein, TRPV1. 303
Taken together, we find that intra-articular injection of AAV-PHP.S-CAG-dTomato in the knee 304 joint transduces mouse DRG neurons in a similar manner to a routinely used retrograde tracer. 305 306 2. Excitatory Gq-DREADD delivered intra-articularly by AAV-PHP.S-hSyn-hM3D(Gq)-307 mCherry does not change spontaneous pain behavior, but provokes a deficit in motor 308
coordination. 309
Next we tested whether AAV-PHP.S can deliver functional hM3D(Gq) cargo into knee neurons 310 via intra-articular injection, using whole-cell patch clamp on acutely dissociated neurons 311 isolated from mice with no previous exposure to the DREADD activator Compound (C21). C21 312 was chosen as the DREADD activator since it has good bioavailability (plasma concentration 313 measured to be at 57% 1 hour post injection), is not converted into clozapine or clozapine-N-314 oxide (29) and had no off-target effect in the behavioral tests conducted in this study in naïve 315 mice not injected with DREADDs ( Fig S2) . Gq-DREADDs couple to GqPCR pathways and thus 316 their activation causes neuronal excitation (9). Therefore, we hypothesized that when incubated 317 with 10 nM C21, virally transduced neurons would be hyperexcitable compared to virally 318 transduced neurons bathed in normal extracellular solution (ECS). In agreement with this 319 hypothesis, we observed an increased number of mostly small and medium diameter ( Fig S3) 320 mostly nociceptive (characterized by having an AP half peak duration > 1 ms and with a "hump" 321 during repolarization, Fig S3, (30) ) neurons (Ctrl, 5.3% vs. C21, 27.8% p = 0.03, chi-sq test) 322 firing action potentials (AP) without injection of current in the C21 group (Fig 2A,B, S3 ). 323
Moreover, upon injection of increasing stepwise current injections, the action potential (AP) 324 threshold was decreased (p = 0.02, unpaired t-test) in the C21 group ( Fig 2C) ; no change was 325 observed in other electrical properties measured in these neurons (Table 1 ). Our data also 326 suggest that virally transduced neurons are viable because the reported AP threshold is very 327 similar to what we have observed previously in FB+ knee-innervating neurons (31). 328 329 Based on previous studies (7,8), we hypothesized that the measured increased excitability of 330 knee-innervating neurons in vitro via the Gq-DREADD system would cause pain-like behavior 331 in mice in vivo, which was tested by measuring digging behavior (a measure of spontaneous 332 pain as described previously (7,30)), dynamic weight bearing and rotarod behavior (a measure 333 of motor co-ordination) (31) (Timeline in Fig 2D) . Three weeks after virus injection into both 334 knee joints, mice (n = 8, 4 males, 4 females in each group) injected with vehicle or C21 did not 335
show changes in digging behavior (Digging duration: Pre vs. Post veh, 31.6 ± 3.7 ms vs. 21.3 336 ± 4.4 ms, Pre vs. Post C21, 25.2 ± 4.9 ms vs. 32.7 ± 4.7 ms; Number of burrows: Pre vs. Post 337 veh, 4.6 ± 0.5 vs. 3.5 ± 0.4, Pre vs. Post C21, 3.9 ± 0.7 vs. 3.6 ± 0.5, Fig 2E,F) Fig 2G,H) . By contrast, after injection of C21, mice showed a marked 340 decline in their ability to remain on the rotarod (Pre vs. Post veh, 273.5 ± 27.2 s vs. 243.9 ± 341 32.7 s, Pre vs. Post C21, 336.1 ± 12.9 s vs. 249.0 ± 18.9 s, p = 0.002, paired t-test) suggesting 342 a deficit in their motor co-ordination ( Fig 2I,J) . DRG for all virus injected mice were visualized 343 under a fluorescence microscope to check for viral transduction and a subset of these DRG were 344 further analyzed to reveal similar transduction profiles between AAV-PHP.S-hSyn-345
GqDREADD-mCherry and AAV-PHP.S-CAG-dTomato ( Fig S3) CFA knee: pre CFA day, 3.1 ± 0.02 mm, post CFA day, 4.0 ± 0.05 mm, n = 24, p < 0.0001, 358 paired t-test, Fig 3A,B) and has been previously shown to increase the excitability of knee 359 neurons innervating the inflamed knee compared to those innervating the contralateral side (7). 360
The post-CFA knee measurements were conducted at the end of behavioral measurements, thus 361 suggesting that regardless of Gi-DREADD activation knee inflammation persisted at 24-hour 362 post-CFA injection. 363
364
We hypothesized that incubating Gi-DREADD expressing knee neurons from the CFA side 365 with C21 would reverse this increased neuronal excitability. Using whole-cell patch clamp 366 electrophysiology of small and medium diameter ( Fig S4) knee neurons, although there was no 367 change in the resting membrane potential across any condition ( Fig 3C, Table 2 ), the percentage 368 of CFA knee neurons firing spontaneous AP decreased after Gi-DREADD activation (CFA, 369 15% vs. CFA+ C21, 0%, p = 0.02, chi-sq test, Fig 3C,S3) . Moreover, in the absence of Gi-370 DREADD activation, CFA knee neurons had a decreased AP threshold compared to neurons 371 from the control side, but the AP threshold of CFA knee neurons that were incubated in C21 372 was similar to that of neurons from the control side (p = 0.005, ANOVA, Fig 3D) . These results 373 suggest that Gi-DREADD activation reverses CFA-induced increase in nociceptor (based upon 374 the criteria mentioned above, Fig S4) excitability in vitro. Other electrical properties between 375 groups were unchanged (Table 2) . 376
377
The ability of Gi-DREADD to modulate pain behavior in DRG neurons is unclear with one 378 study showing an increase in latency to both thermal and mechanical stimuli (15), but another 379
showing only an increase in the paw withdrawal latency to thermal stimuli (14). Nevertheless, 380 based on the in vitro results in these studies, we hypothesized that activation of Gi-DREADDs 381 in knee neurons post CFA would reverse spontaneous pain behavior in mice (timeline in Fig  382   3E ). In the control cohort of mice (n = 9, 5 males, 4 females) that received vehicle 24-hours 383 after CFA injection, the CFA-induced decrease in digging behavior persisted compared to pre 384 CFA (Digging duration: Pre CFA, 29.6 ± 2.7 ms, post CFA 16.6 ± 4.0 ms, post veh, 9.8 ± 2.8 385 ms, p = 0.0005, repeated measures ANOVA; Number of burrows: Pre CFA, 4.8 ± 0.3, post CFA 386 2.9 ± 0.3 ms, post veh, 2.3 ± 0.5 ms, n = 9, p < 0.0001, repeated measures ANOVA, Fig 3F) . 387 However, when C21 was administered to a separate cohort of mice (n = 11, 7 males, 4 females) 388 24-hours after CFA injection, there was a marked recovery in digging behavior (Digging 389 duration: Pre CFA, 29.7 ± 4.5 ms, post CFA 7.8 ± 1.9 ms, post C21, 19.0 ± 3.9 ms, p = 0.0002, 390 repeated measures ANOVA; Number of burrows: Pre CFA, 4.5 ± 0.3, post CFA 2.4 ± 0.3 ms, 391 post C21, 3.6 ± 1.4 ms, p = 0.0005, repeated measures ANOVA, Fig 3G) suggesting that 392 decreasing the excitability of knee neurons via Gi-DREADD reduces inflammation induced 393 spontaneous pain that is associated with an increase in the feeling of well-being demonstrated 394 by more digging. In contrast, acute chemogenetic inhibition of knee neurons was insufficient to 395 reverse the CFA-induced deficit in dynamic weight bearing (Rear left weight bearing as % of 396 body weight: Pre CFA, 26.2 ± 2.0, post CFA, 10.6 ± 1.7, post veh, 11.6 ± 1.5, p < 0.0001; Pre 397 CFA, 26.1 ± 1.1, post CFA, 12.4 ± 1.4, post C21, 13.3 ± 2.2, p < 0.0001, repeated measures 398 ANOVA, Fig 3H,I) which might be because gait changes relating to weight bearing is more 399 reflective of changes in joint biomechanics that are difficult to reverse by analgesics (32). 400 Furthermore, no change in rotarod behavior was observed following CFA-induced knee 401 inflammation suggesting that this model does not cause an overt change in gross motor function 402 and similarly Gi-DREADD activation also had no effect (Pre CFA, 303.8 ± 18.3 s, post CFA, 403 315.9 ± 11.9 s, post veh, 306.6 ± 16.8 s; Pre CFA, 282.7 ± 17.3 s, post CFA, 286.4 ± 25.3 s, 404 post C21, 317.4 ± 10.3 s, Fig 3J,K) . DRG for all virus injected mice were visualized under a 405 fluorescence microscope to check for viral transduction (Fig S4) . The findings in this study show that the AAV-PHP.S serotype can retrogradely deliver cargo 431 to DRG neurons in a peripheral tissue-specific manner when injected into the knee joints without 432 the need for invasive procedures or the requirement to generate transgenic mice. The transduction 433 efficacy of the virus is similar to the widely used retrograde tracer, FB. In-line with other co-434 labelling studies (33), the ~40% co-localization of AAV-PHP.S and FB fluorescence suggests that 435 not all knee neurons are labeled by either tracer and the less than 100% co-labeling is possibly due 436 to their differing modes of retrograde transfer (34, 35) . Furthermore, we report that ~30% of labelled 437 neurons are TRPV1+, which fits with the previously reported identity of knee-innervating neurons 438 as a subset being ~39% TRPV1+, ~53% CGRP+ and largely IB4 non-binding (28,39). 439
Using this system, we show that it is possible to increase or decrease knee neuron 440 excitability in vitro when Gq or Gi-DREADD cargoes were delivered by AAV-PHP.S respectively 441 and hence provide joint specific pain control. This result can also be extended to study the role of 442 anatomically specific neuronal excitability when exposed to a variety of stimuli or pharmacological 443 interventions. In vivo, we restricted our chemogenetic activation to a short duration to reflect acute 444 pain and within this timeframe saw no spontaneous pain-like behavior with activation of Gq-445 DREADD in knee neurons. We surmise that Gq-mediated sub-threshold activation (36) of the 446 relatively low percentage of DRG neurons did not provide sufficient nociceptive input to drive 447 change in ethologically relevant pain behavior; whereas the observed decrease in coordination 448 suggests that we have behaviorally engaged the virally transduced neurons. Furthermore, we note 449 that intra-articular injection described here would transduce DREADDs to both nociceptive and 450 non-nociceptive population of knee neurons, therefore, a clear nocifensive behavior might not be 451 apparent, i.e. a limitation of this study is that distinct subpopulations of knee neurons are not 452 targeted, but future studies could address this once such populations have been described for the 453 knee as has already been conducted for the colon (5). Future studies using a repeated dosing strategy 454 could also be employed in our system for modelling chronic pain, being cautious of the potential 455 risk of receptor desensitization (9). 456
Perhaps more relevant to future clinical applications in arthritic pain is the ability of Gi-457
DREADDs to reverse pain behavior by decreasing neuronal excitability of knee neurons. Indeed, 458
we show that Gi-DREADD activation restores a deficit in digging behavior induced by 459 inflammatory knee pain, similar to previous reports demonstrating normalization of 460 burrowing/digging by non-steroidal anti-inflammatory drugs (41,42) and a peripherally restricted 461 TRPV1 antagonist (7) after joint pain induced depression of this behavior. This strategy can be 462 further refined to selectively inhibit genetically specific subpopulation of knee neurons by 463 combining Cre-inducible viruses with their corresponding Cre-expressing transgenic mouse lines, 464 and hence provide insights into relative contributions of different knee neuron sub-populations in 465 arthritic pain. Selectively exciting specific knee neuron sub-populations with Gq-DREADD might 466 also produce pain-like behaviors that were not observed in this study. We also report that the CFA-467 induced deficit in weight bearing was not reversed following activation of Gi-DREADD in knee 468 neurons, consistent with a previous report observing that reversal of deficits in gait changes are 469 difficult to achieve with analgesics (32). 470
Although findings from this study imply that modulating excitability of anatomically 471 specific peripheral neurons could control arthritic pain, a number of challenges remain to be 472 addressed before their clinical translation. Since virus transduction and expression profile is 473 different between non-human primates and rodents, the expression profile of AAV-PHP.S needs to 474 be first validated in non-human primates (37). Additional work is also required to engineer more 475 PNS specific AAVs and to optimize DREADDs (38) and their corresponding ligands (39) for 476 increasing transduction efficiency and regulating dosing. 477
Overall, the present study provides initial proof-of-concept that peripheral tissue innervating 478 DRG neurons can be specifically modulated by AAVs, opening the door to future studies on gene 479 therapy in controlling arthritic pain. 
